The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRAX | +264% | -61.91% | -17.54% | -41% |
| S&P | +13.09% | +85.73% | +13.17% | +97% |
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. It is a targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.02M | -109.0% |
| Gross Margin | 99.37% | 20.9% |
| Market Cap | $1.12B | 9.2% |
| Market Cap / Employee | $9.62M | 0.0% |
| Employees | 116 | 41.5% |
| Net Income | -$73.93M | -42.4% |
| EBITDA | -$78.34M | -38.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $149.53M | -11.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.44M | -64.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -67.20% | -9.4% |
| Return On Invested Capital | -114.78% | 9.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$64.74M | -137.9% |
| Operating Free Cash Flow | -$64.74M | -137.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.58 | 1.65 | 1.95 | 2.76 | 13.17% |
| Price to Sales | 179.78 | 98.18 | 116.29 | 156.08 | -76.95% |
| Price to Tangible Book Value | 3.58 | 1.65 | 1.95 | 2.76 | 13.17% |
| Enterprise Value to EBITDA | -17.94 | -6.30 | -7.93 | -11.46 | -11.04% |
| Return on Equity | -71.0% | -63.6% | -61.0% | -75.2% | 16.87% |
| Total Debt | $1.37M | $1.07M | $0.76M | $0.44M | -73.73% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
